<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
--------------
Date of Report (Date of earliest event reported): September 8, 2000
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Massachusetts 000-19319 04-3039129
----------------------- -------------------- -------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
</TABLE>
130 WAVERLY STREET
CAMBRIDGE, MA 02139
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 577-6000
--------------------------------------------------------------------------------
Page 1 of 8 pages
<PAGE>
ITEM 5. OTHER EVENTS.
On September 8, 2000, we publicly disseminated a press release
announcing our intention to redeem our 5% Convertible Subordinated Notes due
2007. The information contained in the press release is incorporated herein
by reference and filed as Exhibit 99.1 hereto.
Also on September 8, 2000, we publicly disseminated a press release
announcing a $200 million private offering of Convertible Subordinated Notes.
The information contained in the press release is incorporated herein by
reference and filed as Exhibit 99.2 hereto.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 Press Release dated September 8, 2000, "Vertex Pharmaceuticals
Announces its Intention to Redeem its 5% Convertible Subordinated
Notes Due 2007."
99.2 Press Release dated September 8, 2000, "Vertex Pharmaceuticals
Announces $200 Million Private Offering of Convertible Subordinated
Notes."
Page 2 of 8 pages
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: September 8, 2000 By: /s/ Thomas G. Auchincloss, Jr.
---------------------------------
Name: Thomas G. Auchincloss, Jr.
Title: Vice President, Finance
Page 3 of 8 pages
<PAGE>
EXHIBIT INDEX
Exhibit Sequential
Number Description Page Number
------- ----------- -----------
99.1 Press Release dated September 5
8, 2000, "Vertex Pharmaceuticals
Announces its Intention to Redeem
its 5% Convertible Subordinated
Notes Due 2007."
99.2 Press Release dated September 7
8, 2000, "Vertex Pharmaceuticals
Announces $200 Million Private
Offering of Convertible
Subordinated Notes."
Page 4 of 8 pages
